» Articles » PMID: 20973434

An Update on Cancer Survival

Overview
Journal Health Rep
Specialty Public Health
Date 2010 Oct 27
PMID 20973434
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Statistics Canada routinely produces cohort-based estimates for cancer survival; the most recent were based on cases diagnosed from 1992-2000. This report provides predicted survival estimates for cases diagnosed more recently. Using records from the Canadian Cancer Registry linked to the Canadian Vital Statistics Death Data Base, cancer- and age-specific estimates of relative survival have been calculated for 2004-2006. The five-year relative survival ratio (RSR) for all cancers combined was 62%, and ranged from 6% for pancreatic cancer to 98% for cancer of the thyroid. The RSR was typically higher at younger than older ages, with exceptions for some common cancers. From 1992-1994 to 2004-2006, the five-year RSR for a number of cancers increased--usually slightly, but in some cases, appreciably (for example, the age-standardized RSR for non-Hodgkin lymphoma rose from 51% to 63%; for leukemia, from 44% to 54%; and for liver, 9% to 17%).

Citing Articles

Nomogram for predicting post-progression-free survival in patients with recurrent pancreatic ductal adenocarcinoma after radical surgery: a retrospective analysis.

Qin D, Xi P, Huang K, Jiang L, Yao Z, Wei R Front Med (Lausanne). 2024; 11:1486750.

PMID: 39712186 PMC: 11659012. DOI: 10.3389/fmed.2024.1486750.


Prognostication for recurrence patterns after curative resection for pancreatic ductal adenocarcinoma.

Ang A, Michaelides A, Chelala C, Ullah D, Kocher H Ann Hepatobiliary Pancreat Surg. 2024; 28(2):248-261.

PMID: 38556877 PMC: 11128784. DOI: 10.14701/ahbps.23-149.


Prognostic effect of CD73 in pancreatic ductal adenocarcinoma for disease-free survival after radical surgery.

Qin D, Wei R, Huang K, Wang R, Ding H, Yao Z J Cancer Res Clin Oncol. 2023; 149(10):7805-7817.

PMID: 37032378 DOI: 10.1007/s00432-023-04703-4.


Opioid Use at End-Of-Life Among Nova Scotia Patients With Cancer.

Minard L, Fisher J, Broadfield L, Walsh G, Sketris I Front Pharmacol. 2022; 13:836864.

PMID: 35401210 PMC: 8987150. DOI: 10.3389/fphar.2022.836864.


Comparative Recurrence Analysis of Pancreatic Adenocarcinoma after Resection.

He C, Cai Z, Zhang Y, Lin X J Oncol. 2021; 2021:3809095.

PMID: 34721578 PMC: 8553472. DOI: 10.1155/2021/3809095.